title: The adaptive stroma joining the antiangiogenic resistance front.
abstract: Resistance to antiangiogenic therapies in cancer involves both tumor cells and stromal components, but their relative contributions differ in each cancer subtype. In this issue of the JCI, Cascone et al. describe a stromal adaptation to antiangiogenic therapy in non-small cell lung carcinoma (NSCLC) models that include EGFR-driven vascular remodeling promoting resistance to VEGF inhibition. Their results suggest that the added benefit of dual VEGF/R and EGFR targeting in these models could be clinically relevant to fight resistance in NSCLC patients.
authors: Tumor Angiogenesis Group, Translational Research Laboratory, Catalan Institute of Oncology - IDIBELL, L'Hospitalet de Llobregat, Spain. ocasanovas@iconcologia.net
authors: Oriol
authors: O
authors: Casanovas
mesh_terms: D000222:Adaptation, Physiological; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply / Q000188:drug therapy; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy; D008954:Models, Biological; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D017154:Stromal Cells / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor